Baader Bank Aktiengesellschaft’s Carisma Therapeutics CARM Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,515	Closed	-$517	–	443
2025 Q4	$517	Buy	+19,515	New	+$4.89K	﹤0.01%	436
2025 Q3	–	Sell	-18,404	Closed	-$4.45K	–	506
2025 Q2	$4.45K	Buy	+18,404	New	+$4.92K	﹤0.01%	432
2025 Q1	–	Sell	-11,804	Closed	-$4.42K	–	434
2024 Q4	$4.42K	Buy	+11,804	New	+$9.73K	﹤0.01%	373

Other funds holding CARM

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

GSEP

Golden State Equity Partners South Coast Metro, California $37.1M AUM 20.75% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CARM Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of Carisma Therapeutics (CARM) in Q1 2026, closing a stake of 19,515 shares — an estimated $517 sold.

Baader Bank Aktiengesellschaft first reported a position in CARM in Q4 2024 and held it in 3 quarters. The position peaked at $4.45K in Q2 2025. 3 funds tracked by Wall St. Rank hold CARM as of Q1 2026.

Baader Bank Aktiengesellschaft reported no remaining Carisma Therapeutics position as of Q1 2026 after selling out during the quarter.
Baader Bank Aktiengesellschaft sold 19,515 Carisma Therapeutics shares in Q1 2026, an estimated $517.
Baader Bank Aktiengesellschaft first reported a position in Carisma Therapeutics in Q4 2024 and held it in 3 quarters.
Baader Bank Aktiengesellschaft's Carisma Therapeutics position peaked at $4.45K in Q2 2025.
3 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.